INBX · Inhibrx Biosciences Inc
United States · RS rating 37 · As of 2026-11-03
| Price | 81.08 USD |
|---|---|
| 1-day change | +12.4% |
| RS rating (overall / 1M / 3M / 12M) | 37 / 28 / 59 / 50 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 40 / 34 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +7.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +42.8% |
| Market cap (USD) | $1.8B |